TP53 and neoplasm: In this context, the inhibition of protein phosphatase 2A (PP2A) activates p53, by phosphorylation at Serine20 and Serine46 residues mediated by CDK-5, restoring p53 functionality and resulting in a regression of tumor growth in vivo [63].